The Interesting Life Company

The agent is the product rather than an addition to one, which points toward the top grade, and the technical basis is entirely unspecified, which prevents it. Conversational elicitation of medical and lifestyle disclosures, a running prediction that updates as information arrives, and generated plain English explanations of an underwriting decision are all inference shaped, and the vendor, the distributing platform and several trade publications describe it as an artificial intelligence agent.

What is absent is anything establishing that models rather than encoded rules carry the work: the underwriting knowledge came from two named industry consultants, which is exactly the profile of an expert system, and the company also sells ratings and explanatory content that survive the removal of any model. An unspecified basis does not earn the top grade on this axis any more than an unspecified credential earns one elsewhere.

One structural safeguard is built into what the product is, and no oversight design is published on top of it. The output is explicitly an indication of a likely outcome ahead of the real underwriting decision, which means the insurer's actual assessment follows and corrects it, so a wrong answer is caught by the process rather than acted on as final. That is product scope rather than governance.

Searched for a confidence measure attached to an indication, a statement of what the adviser is shown about how firm a prediction is, an account of how the tool behaves on conditions outside its knowledge, or any feedback mechanism comparing indications against actual outcomes, and located none.

The entire value of this product is the accuracy of a prediction and the accuracy is unpublished. Searched for a hit rate comparing indicated outcomes against actual insurer decisions, an error rate by condition type, a benchmark, a validation method, a statement of which insurers' underwriting philosophies are represented and how current that representation is, and any revalidation cadence as insurer appetite changes, and located none. The last point is the sharpest: underwriting terms move as insurers reprice, so a tool predicting them decays unless it is maintained, and nothing describes how or how often.

The strongest signal available is a distribution endorsement and this index does not treat that as a customer reference, which is a distinction worth stating because the two look similar. A listed technology company chose to make the tool exclusively available on its platform and its head of business development for sourcing is quoted by name praising it, which is a commercial judgement by a party with something at stake. It is not a firm reporting what happened when it used the product.

Searched for a named adviser firm, an adoption figure, a measured reduction in case research time or any comparison of predicted against actual underwriting outcomes, and located none. The product launched in February 2026, so a thin record is expected rather than surprising.

Searched for a statement on whether the medical and lifestyle disclosures entered by advisers are retained, used to improve the tool, or used to train, tune or evaluate any model, and located none. The question is not hypothetical for a product of this design, because a tool predicting underwriting outcomes improves most directly by learning from the outcomes of cases it has seen, which would mean accumulating a body of real health disclosures and their results. Whether that is happening, and on what basis, is unstated in either direction.

This is the most consequential unanswered row on the record and it deserves stating plainly. The tool works by taking an adviser through a client's medical history, existing conditions, medications and lifestyle, which is health information about an identifiable person and among the most protected categories of personal data there is.

Searched for a privacy statement, a description of what is retained after a session, a deletion commitment, a statement of whether disclosures are stored at all or processed transiently, and any account of the lawful basis on which health data reaches the tool before an insurance application exists, and located none of it.

Recorded as an unverified absence. Searched for an enumerated attestation, a named information security standard, an audit report or a trust page, and located none, and no dedicated security page was found to read. The consideration is sharper than the vendor's size suggests, because the tool handles medical disclosures about identifiable individuals, and because it is distributed inside a platform whose operator will have run its own vendor review before granting exclusivity. That review is the likeliest source of a published position and is the queued check.

The company holds no licence and requires none as a technology supplier, and no penalty attaches to that. The position it occupies is worth describing precisely because it sits close to a regulated act without performing one: an indication of how an insurer will treat a client's disclosures shapes which product an adviser recommends, and the recommendation is the regulated act, carried out by the adviser firm under its own permissions. Nothing published addresses how a firm records that an indication informed a recommendation, or what an examiner reviewing a protection sale would be shown.

Few products in this index sit closer to the questions this axis exists for. Predicting an underwriting outcome from medical and lifestyle disclosures means making distinctions on the basis of health conditions, disability, mental health history, age and behaviour, which is the precise territory where insurance discrimination rules, equality law and consumer fairness expectations apply.

A prediction that is systematically pessimistic for a category of condition would discourage advisers from pursuing applications for those clients, which produces exclusion without any insurer ever declining anyone. Searched for any evaluation across condition types, any fairness testing or any account of how the knowledge base was assembled and checked, and located none.

Searched for a warranty, an accuracy commitment, a correction obligation or any allocation of responsibility between vendor and adviser firm, and located none, and no disclaimer stating that indications are guidance only was located either, which is itself notable for a predictive tool.

The exposure runs to the client rather than only the firm: an adviser who sets expectations from an indication and is later contradicted by the insurer has given a client a worse experience than saying nothing, and a client discouraged from applying at all never becomes a case anyone reviews. No route for a client to see or contest an indication is described.

Searched the company site, the launch announcement and the distribution announcement for a provider, a model family, a version or an inference host, and located none. Nothing published distinguishes work performed by the company from work called out to an external service, which matters more here than for most vendors in this index because the content being processed is health information: an adviser cannot establish from public material whether a client's medical disclosures reach a third party during a conversational session, or which one.

One integration exists and it is a distribution arrangement rather than an integration estate. The tool sits inside a major protection sourcing platform, alongside product comparison, which is a sensible placement because it puts the underwriting indication at the moment the adviser is choosing a product.

Searched for a programmatic interface, a connection to any adviser back office or client relationship system, a link to insurer underwriting engines, or any second channel, and located none. The exclusivity is a commercial choice rather than a technical limit, and it caps reach at the users of one platform.

Recorded as an unverified absence. The tool is reached through a browser inside a sourcing platform and nothing about topology is published. Searched for hosting arrangements, storage location, residency commitments or any statement about where health disclosures are processed, and located none.

The exclusive distribution arrangement raises a question the published material does not reach, namely whether data entered into the tool sits within the sourcing platform's environment or the vendor's own, and an adviser firm cannot establish which from anything published.

One useful commercial fact is published: the tool is licensed separately rather than included in the sourcing platform subscription, so an adviser firm knows it faces an additional line rather than discovering it later. No rate, tier, per user basis or trial arrangement was located, and no pricing route outside the exclusive channel is described. For a tool sold to small advice firms, where a per seat figure determines whether it is adopted at all, the absent number is the one that decides.

This is genuinely narrow rather than merely young, which is what this grade means. The buyer is a United Kingdom protection adviser, the scope is three product lines covering life, critical illness and income protection, and since April 2026 the tool reaches those advisers through a single sourcing platform on an exclusive basis. There is no second jurisdiction, no adjacent insurance line, no insurer facing product and no direct channel described alongside the exclusive one.

The addressable population is real and the vendor knows it precisely, since protection advice is a defined market, but by the measure this axis applies the coverage is one buyer type in one country reached one way.